Mar 29, 2024  
2021-2022 College Catalog 
    
2021-2022 College Catalog [ARCHIVED CATALOG]

PHT 172 - Drug Therapy I

4 Credits, 4 Contact Hours
4 lecture periods 0 lab periods

Overview of the relationship between the central nervous system (CNS), the autonomic nervous system (ANS) and pharmaceutical therapy. Includes anatomy and physiology of the CNS, neurotransmission and disorders of the CNS, therapeutic applications of drugs affecting the CNS, and characteristics of drugs of the CNS. Also includes anatomy and physiology of the ANS, drug action on ANS neurotransmission, disorders treated with autonomic drugs, and types and characteristics of autonomic drugs.

Prerequisite(s): With a C or better: REA 091  or assessment into REA 112  and WRT 090  or assessment into WRT 101 , and PHT 170  or concurrent enrollment.



Course Learning Outcomes
  1. Identify characteristics of the anatomy and physiology of the Central Nervous System and the Autonomic Nervous System.
  2. Identify the disorders and disease states of the Central Nervous System and the Autonomic Nervous System.
  3. Describe nerve impulse transmission in the Central Nervous System.
  4. Describe cholinergic and adrenergic neurotransmission in the Autonomic Nervous System.
  5. Identify drugs needed to treat specific disorders in the Central Nervous System and the Autonomic Nervous System.
  6. List specific characteristics of each drug, including the following: indications for use; dosage form(s); usual dosage; side effects and toxicity; interaction with other drugs; storage requirements; special preparation procedures; generic/trade names; and mechanism of action.

Outline:
  1. Introduction

II.          Central Nervous System

  1. Anatomy and physiology
  1. Brain and spinal cord
  2. Subcortical brain regions
  3. Ascending reticular activating system
  4. Limbic system
  5. Hypothalamus
  6. Medial forebrain bundle
  7. Periventricular system
  8. Spinal cord
  1. Neurotransmission
  1. CNS neurons
  2. Noradrenergic pathways
  3. Dopaminergic pathways
  4. Serotonergic pathways
  5. Cholinergic pathways
  6. GABA-ergic pathways
  7. Glycine pathways
  1. Disorders
  1. Pain disorders
  2. Sleep disturbances
  3. Sleep-wake disorders
  4. Disorders that occur only during sleep
  5. Insomnia
  6. Seizures
  7. Affective disorders
  8. Psychoneurosis
  9. Organic brain psychosis
  10. Schizophrenia
  11. Attention deficit disorder
  12. Alzheimer’s disease
  13. Parkinsonism
  14. Infections
  1. Therapeutic applications of drugs affecting CNS
  1. General anesthetics
  2. Local anesthetics
  3. Sedatives and hypnotics
  4. Anticonvulsant drugs
  5. Narcotic analgesics
  6. Narcotic analgesic antagonists
  7. CNS stimulants
  8. Psychotherapeutic drugs
  9. Anticonvulsant drugs
  10. Antiparkinsonism drugs
  11. Anti-infectives
  1. Specific characteristics of CNS drugs
  1. Indications for use
  2. Dosage form(s)
  3. Usual dosage
  4. Side effects and toxicity
  5. Significant drug interactions
  6. Storage requirements
  7. Special preparation procedures
  8. Generic/trade names
  9. Mechanisms of action
  1. Autonomic Nervous System
  1. Anatomy and physiology
  1. Parasympathetic division
  2. Sympathetic division
  3. Characteristics of the ANS
  1. Drug action on ANS neurotransmission
  1. Cholinergic transmission
  2. Acetylcholine receptor
  3. Nicotinic acetylcholine recepter
  4. Muscarinic acetylcholine receptor
  5. Adrenergic transmission
  6. Adrenergic receptor
  7. Alpha-adrenergic receptors
  8. Beta-adrenergic receptors
  1. Disorders treated with autonomic drugs
  1. Diseases treated with cholinergic drugs
  2. Diseases treated with cholinergic blocking drugs
  3. Diseases treated with adrenergic drugs
  4. Diseases treated with adrenergic blocking drugs
  1. Autonomic drugs
  1. Cholinergic drugs
  2. Anticholinesterase drugs
  3. Muscarinic receptor blocking drugs
  4. Drugs blocking nicotinic receptors at the neuromuscular junction
  5. Adrenergic drugs
  6. Adrenergic blocking drugs
  7. Drugs that block adrenergic neurons
  8. Drugs that reduce central adrenergic outflow
  9. Drugs that inhibit monoamine oxidase
  10. Drugs that inhibit catecholamine synthesis
  1. Specific characteristics of drugs of ANS
  1. Indications for use
  2. Dosage form(s)
  3. Usual dosage
  4. Side effects and toxicity
  5. Significant drug interactions
  6. Storage requirements
  7. Special preparation procedures
  8. Generic/trade names
  9. Mechanisms of action


Effective Term:
Fall 2016